Director, Process Chemistry

Bill Connors, Ph.D.

Bill joined atai Life Sciences in 2022. Previously, Dr. Connors was Director of Chemistry with Summit Therapeutics where he was responsible for drug substance manufacturing for the phase 3 compound, ridinilazole.

He has held several positions in both research and development, including Epizyme where he contributed to the marketed product, Tazverik® and several early-stage compounds, Genocea Biosciences where he led the drug substance efforts for Genocea’s personalized peptide-based cancer immunotherapy program, and Ensemble Therapeutics where he advanced Ensemble’s DNA-Programmed Chemistry drug discovery platform in the production of peptidomimetic libraries.

Dr. Connors holds a B.S. in Biology from Virginia Commonwealth University, a Ph.D. in Organic Chemistry from Tufts University, and an M.B.A. from the Isenberg School of Management at the University of Massachusetts Amherst.

<<  Back to our team